- The nootropic peptides most discussed for brain fog, Semax, Selank, Dihexa, Noopept, and Cerebrolysin, share a pattern of promising preclinical mechanisms and thin, sex-blind human data.
- Not one of these compounds has indexed human data reporting cognitive outcomes by sex, even though many studies enrolled female subjects.
- Brain fog around perimenopause is a common and real experience, yet none of these research-use peptides has been studied for it in women.
Brain fog is one of the most searched complaints in women's health, and it spikes around the perimenopausal transition, when shifting hormones and disrupted sleep can make concentration and word-finding feel unreliable. Into that gap steps a cluster of nootropic peptides, marketed for focus and mental clarity: Semax, Selank, Dihexa, Noopept, and Cerebrolysin. They are among the most hyped compounds in this database and among the least studied in women. This page lays out the mechanisms honestly and marks where the human evidence, and the female evidence, actually run out.
The BDNF cluster: Semax and Selank
Semax, an ACTH(4-10)-derived peptide, and Selank, a tuftsin-analog heptapeptide, are the two most-cited names here. Both were developed in Russia and both have been studied for their relationship to brain-derived neurotrophic factor (BDNF) signaling, the pathway associated with neuronal growth and synaptic plasticity. Semax has additionally been characterized against nerve-growth-factor expression and dopaminergic and serotonergic signaling; Selank against GABAergic signaling and enkephalin-degradation pathways. Their human data is limited, and the two are compared directly in the Selank vs Semax comparison.
Dihexa and Noopept: targeted mechanisms
Dihexa is a small compound derived from angiotensin IV, studied in cognition models for its association with hepatocyte growth factor (HGF) and its receptor c-Met, a signaling axis characterized against synaptogenesis and dendritic connectivity in preclinical systems. Noopept is a proline-containing dipeptide, structurally related to the racetam family, studied for its association with nerve-growth-factor and BDNF expression and for antioxidant and neuroprotective signaling. Both link a compact structure to neurotrophic pathways, which is what makes them convenient laboratory tools, and both remain preclinical for the cognitive claims attached to them.
Cerebrolysin: a composite preparation
Cerebrolysin is different in kind: a peptide preparation derived from porcine brain tissue, a mixture of low-molecular-weight peptides and amino acids rather than a single molecule. It has been studied in preclinical models for its relationship to neurotrophic pathways associated with neuronal survival, growth, and plasticity, and it is used as a composite neurotrophic material rather than a single-target agent, which complicates clean mechanistic interpretation.
The hype-versus-evidence gap
Put the five together and a familiar shape appears. The mechanisms are plausible and, in several cases, reasonably specific; the human efficacy data is thin; and the female data is effectively absent. For Semax and Selank, many studies included female subjects and none reported sex-stratified outcomes, with no cycle, hormonal, or menopausal data on record. Dihexa, Noopept, and Cerebrolysin sit largely in preclinical systems, where sex-blind design is the default. Whether any of these mechanisms translate the same way across female physiology is an open research question our review tracks, not a settled fact to market against.
Cognitive changes around perimenopause are common and legitimate, and they deserve real evaluation. None of these research-use peptides has been studied for perimenopausal brain fog in women, and nothing here is a treatment for it. Persistent cognitive changes are worth raising with a clinician.
Some early studies report dose ranges for these compounds, but most have no established therapeutic dose in the relevant jurisdictions. Any figures in the literature are research context only. This site does not publish personal dosing, protocols, or medical advice.
The nootropic corner is where enthusiasm and evidence diverge most, and the divergence is widest precisely for the women, those navigating perimenopausal cognitive change, most likely to go looking. That mismatch is the story worth telling plainly. For the full per-compound record of what was studied and in whom, see the Semax, Selank, Dihexa, Noopept, and Cerebrolysin profiles.